Glp 1 and gip ppt to pdf

Posted on Friday, June 4, 2021 10:44:17 PM Posted by Alexandrin B. - 05.06.2021 and pdf, for pdf 4 Comments

glp 1 and gip ppt to pdf

File Name: glp 1 and gip ppt to .zip

Size: 2144Kb

Published: 05.06.2021

Neuroprotective effects of glucose-dependent insulinotropic polypeptide in Alzheimer’s disease

GLP-1 receptor agonists differ substantially in their duration of action, frequency of administration and clinical profile. This article reviews the mechanisms of action and clinical evidence for GLP-1 receptor targeting and discusses differences between GLP-1 therapies, focusing particularly on clinical data for the GLP-1 receptor agonist, lixisenatide. Different GLP-1 therapies exert differential effects on fasting and postprandial glycemia both being major determinants of glycemic control. They also slow gastric emptying to different extents, probably accounting for different effects to reduce postprandial glycemia. The GetGoal phase 3 studies in T2DM have confirmed the efficacy of once-daily lixisenatide in reducing plasma glucose and glycated hemoglobin HbA 1c , with a pronounced lowering of postprandial plasma glucose PPG , as monotherapy and as add-on to oral antidiabetic drugs and to basal insulin.

Obesity is a major cause of cardiovascular disease and cancer, and its prevalence is increasing worldwide 1. Thus, it is critical to find effective treatments. An important issue is the regain of weight after different lifestyle interventions. This is at least partly due to resumption of previous lifestyle habits but also has physiological reasons. Importantly, diet composition may be important for weight loss maintenance with a high-protein and low-carbohydrate diet potentially being associated with improved body weight maintenance 2. Diet composition may also impact the secretion of hormones involved in the homeostatic regulation of body weight loss and weight maintenance. A Paleolithic diet is based on fruit, vegetables, eggs, nuts, fish and lean meat and excludes salt, refined sugar, cereals and dairy products.

The glucagon-like peptide-1 GLP-1 is a multifaceted hormone with broad pharmacological potential. GLP-1 also has cardio- and neuroprotective effects, decreases inflammation and apoptosis, and has implications for learning and memory, reward behavior, and palatability. Biochemically modified for enhanced potency and sustained action, GLP-1 receptor agonists are successfully in clinical use for the treatment of type-2 diabetes, and several GLPbased pharmacotherapies are in clinical evaluation for the treatment of obesity. In this review, we provide a detailed overview on the multifaceted nature of GLP-1 and its pharmacology and discuss its therapeutic implications on various diseases. Since its discovery, GLP-1 has emerged as a pleiotropic hormone with a myriad of metabolic functions that go well beyond its classical identification as an incretin hormone.

Slides: GLP-1 receptor agonists: The cardiovascular benefits beyond glucose control

Glucagon-like peptide 1 GLP-1 was initially identified as a gut-derived incretin hormone that augments insulin secretion in a glucose-dependent manner from pancreatic islet beta cells during the postprandial period 1 , 2. Subsequent research discovered that GLP-1 also lowered glycaemia by inhibiting glucagon secretion from pancreatic alpha cells, delaying gastric emptying and mediating induction of satiety 1 — 4. Thus, GLP-1 maintains metabolic homeostasis during the postprandial period via multiple actions. For over a decade now, GLP-1 receptor agonists, which have a much longer half-life than endogenous GLP-1, have been an effective treatment option for type 2 diabetes T2D 5 , 6. Interestingly, studies over more recent years have also identified that GLP-1 has beneficial physiological effects on a variety of tissues such as the cardiovascular and neurological systems and this has high clinical relevance given the multiple and common post-diagnosis complications associated with T2D 1 , 2 , 5 , 7 —

Post hoc analyses of fasting biomarkers and multiple linear regression analysis. Analyze biomarkers of beta-cell function and insulin resistance IR and evaluate WL contributions to IR improvements at 26 weeks. To determine whether improvements in IR were directly attributable to WL, multiple linear regression analysis with potential confounding variables age, sex, metformin, triglycerides, and glycated hemoglobin A1c was conducted. Tirzepatide improved markers of IS and beta-cell function to a greater extent than dulaglutide. IS effects of tirzepatide were only partly attributable to WL, suggesting dual receptor agonism confers distinct mechanisms of glycemic control.


Presentation title. Slide no 12 DPP-4, dipeptidyl peptidase-4; GLP-1, glucagon like peptide-1; SGLT-2, sodium-glucose co-transporter. Cheng AY et Glucagon​-like peptide GIP. Glucose-dependent insulinotropic polypeptide. • amino.


Slides: GLP-1 receptor agonists: The cardiovascular benefits beyond glucose control

Glucose-dependent insulinotropic polypeptide GIP is a member of the incretin hormones and growth factors. Neurons express the GIP receptor, and GIP and its agonists can pass through the blood brain barrier and show remarkable neuroprotective effects by protecting synapse function and numbers, promoting neuronal proliferation, reducing amyloid plaques in the cortex and reducing the chronic inflammation response of the nervous system. Long-acting analogues of GIP that are protease resistant had been developed as a treatment for type 2 diabetes. Novel dual agonist peptides that activate the GIP receptor and another incretin receptor, glucagon-like peptide -1 GLP-1 , are under development that show superior effects in diabetic patients compared to single GLP-1 agonists.

Thank you for visiting nature. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser or turn off compatibility mode in Internet Explorer.

Freeman JS. The Pathophysiologic Role of Incretins. Many patients with type 2 diabetes mellitus T2DM are unable to achieve adequate glycemic control.

Glucagon-like peptide 1 (GLP-1)

Introduction

 - Пожалуй, я куплю тебе билет. Белокурая девушка смотрела на него недоверчиво. - Вы это сделаете? - выдавила она, и глаза ее засветились надеждой.  - Вы купите мне билет домой. О Боже, я вам так благодарна. Беккер растерялся.

COMMENT 4

  • Mice were treated with multiple low dose streptozotocin or hydrocortisone. Luvencio R. - 05.06.2021 at 05:22
  • GLP-1 is an incretin (hormone that increases insulin secretion in Site of Production GIP K-cells (Duodenum and Jejunum) GLP-1 L-cells (Ileum Available at: gmworldwide.org#page=1; 3. Jim D. - 10.06.2021 at 04:39
  • The incretin system in healthy humans: The role of GIP and GLP-1 mechanisms of action of insulin receptor signaling are beyond the scope of this presentation, Paracetamol, glucose, GLP-1 and GIP concentrations in plasma in 8 healthy volunteers after Article Download PDFView Record in Scopus​Google Scholar. Tatgirl82 - 12.06.2021 at 03:47
  • These metrics are regularly updated to reflect usage leading up to the last few days. Dominic Y. - 13.06.2021 at 03:21

LEAVE A COMMENT